References Anderson PM, Schroeder G, Skubitz KM. 1998. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer, 83:1433-9. Anderson PM, Ramsay NK, Shu XO, et al. 1998. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant, 22:339-44. Andriea-Abadic N, Levade T. 2002. Sphingomyelin hydrolysis during apoptosis. Biochem Biophys Acta, 1585:126-34. auf dem Keller U, Krampert M, Kümin A, et al. 2004 Keratinocyte growth factor: effects on keratinocytes and mechanisms of action. Eur J Biol, 83:607-12. Balducci L, Exterrman M. 2000. Management of cancer in the older person: a practical approach. Oncologist, 20:224-37. Barasch A, Peterson DE, Tanzer JM, et al. 1995. Heliun-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer, 76:2550-6. Bardet E, Martin L, Calais G, et al. 2002. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Sem Oncol, 29(suppl 19):57-60. Bellm LA, Epstein JB, Rose-Ped A, et al. 2000. Patients reports of complications of bone marrow transplantation. Support Care Cancer, 8:33-9. Blazar BR, Weisdorf DJ, DeFor TE, et al. 2005. Palifermin (A rHuKGF molecule) is safe and well tolerated in patients (Pts) with hematologic malignancies (HM) undergoing high-dose chemoradiotherapy (HD-CRT) followed by allogeneic hematopoietic stem cell transplant (HSCT) [abstract]. Biol Blood Marrow Transplant, 11(suppl 1):11. Braun S, Hanselmann C, Gassman MG, et al. 2002. Nrf2 transcription factor: a novel target of keratinocyte growth factor action regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol, 22:5492-505. Brizel DM, Wasserman TH, Henke M, et al. 2000. Phase III randomised trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol, 18:3339-45. Cascinu S, Fedeli A, Fedeli SL, et al. 1994. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatatis. Eur J Cancer B Oral Oncol, 30B:234-6. Chedid M, Rubin JS, Csaky KG, et al. 1994. Regulation of keratinocyte growth factor gene expression by interleukin 1. J Biol Chem, 269:10753-7. Chi KH, Chen CH, Chan WK, et al. 1995. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositisin head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol, 13:2620-8. Cowen D, Tardieu C, Schubert M, et al. 1997. Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplan: results of a double blind randomised trial. Int J Radiot Oncol Biol Phys, 38:697-703. Dazzi C, Cariello A, Giovanis P, et al. 2003. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind randomised, placebo-controlled study. Ann Oncol, 14:559-63. Donnelly JP, Bellm LA, Epstein JB, et al. 2003. Antimicrobial therapy to prevent or treat mucositis. Lancet Infect Dis, 3:405-12. Dood MJ, Miaskowski C, Shiba GH, et al. 1999. Risk factors for chemotherapy-induced oral mucositis: dental appliance, oral hygiene, previous oral lesions, and a history of smoking. Cancer Invest, 17:278- 84. Dörr W, Spekl K, Farell C. 2002. Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys, 54:245-51. Oral mucositis and its treatments Elting L, Peterson D, Sonis ST. 2004. Late-breaking information from the 2004 ASCO annual meeting. Oral Mucositis Newsletter, 1:1-12. Epstein JB, Tsang AHF, Warkentin D, et al. 2002. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 94:39-44. Farell CL, Bready JV, Rex KL, et al. 1998. Keratinocyte Growth Factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res, 58:933-9. Finch PW, Rubin JS, Miki T, et al. 1989. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science, 245:752-5. Foote RL, Loprinzi CL, Frank AR et al. 1994. Randomized trial of chlorhexidine mouthwash for alleviation of radiation induced-mucositis. J Clin Oncol, 12:2630-3. Freytes CO, Ratanathorn V, Taylor C, et al. 2004. Phase I/II randomised clinical trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hemotopoietic stem cell transplantation. Clin Cancer Res, 10:8318-24. Frieling JT, Mulder JA, Hendriks T, et al. 1997. Differential induction of pro- and anti-inflammatory cytokines in whole blood by bacteria effects of antibiotic treatment. Antimicrob Agents Chemother, 41:1439-43. Genot MT, Klastersky J. 2005. Low level laser for prevention and therapy of oral mucositis induced by chemotherapy and/or radiotherapy. Curr Opin Oncol, 17:236-40. Graham GJ, Ramenghi U, O’Connor MP, et al. 1992. Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. Br J Haematol, 82:589-95. Henry S, D’Hondt L, André M, et al. 2004. Saccharomyces Cerevisiae fumgemia in a head and neck cancer patient: a case report and review of the literature. Acta Clin Belg, 59:220-2. Hille A, Rave-Frank M, Pradier O, et al. 2003. Effect of keratinocyte growth factor on the proliferatio, clonogenic capacity and colony size of human epithelial tumour cells in vitro. Int J Radiat Biol, 79:119-128. Hsu YR, Nybo R, Sullivan JK, et al. 1999. Heparin is essential for a single keratinocyte growth factor molecule to bind and form a complex with two molecules of the extracellular domain of its receptor. Biochemistry, 38:2523-34. Innocenti M, Moscatelli G, Lopez S. 2002. Efficacy of Gelclair in reducing pain in palliative care patients with oral lesions: preliminary findings from an open pilot study. J Pain Symptom Manage, 24:456-7. Jebb SA, Osborne RJ, Maughan TS, et al. 1994. 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer, 70:732-5. Just N, Tillie-Leblond I, Guery BP, et al. 2003. Keratinocyte growth factor (KGF) decreases ICAM-1 and VCAM-1 cell expression on bronchial epithelial cells. Clin Exp Immunol, 132:61-9. Kannan V, Bapsy PP, Anantha N et al. 1997. Efficacy and safety of granulocyte- macrophage colony-stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma. Int J Radiot Oncol Biol Phys, 37:1005-10. Karthaus M, Rosenthal C, Huebner G, et al. 1998. Effect of topical oral G- CSF on oral mucositis: a randomized placebo-controlled trial. Bone Marrow Transplant, 22:781-5. Komaki R, Lee JS, Kaplan B et al. 2002. Randomised phase III study of chemoradiation with or without amifostine for patients with favourable performance status inoperable stage II and III non-small cell lung cancer: preliminary results. Semin Radiot Oncol, 12(suppl 1):46-9. Kuenen BC, Levi M, Meijers JC, et al. 2003. Potential role of platelets in endothelial damage during treatment with gemcitabine and the angiogenesis inhibitor SU5416. J Clin Oncol, 21:2192-8. Larson P, Miakowski C, MacPhail L, et al. 1998. The PRO-SELF mouth aware program: an effective approach for reducing chemotherapy-induced mucositis. Cancer Nurs, 21:263-8. Therapeutics and Clinical Risk Management 2006:2(2) 167